Viking takes delivery of new Viking Rota river ship, expands European fleet
Bitget2026/10/07 20:16Viking Holdings took delivery of the Viking Rota, a 190-passenger river ship, expanding its European river fleet. The vessel will operate on the Rhine, Main, and Danube, supporting capacity growth on core itineraries. Committed orderbook targets 18 additional river ships by 2028, lifting the river fleet to 114 ships. Plans also call for 11 additional ocean ships by 2032, plus two expedition ships by 2031. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Holdings Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261007775998) on October 07, 2026, and is solely responsible for the information contained therein.
- Viking Holdings took delivery of the Viking Rota, a 190-passenger river ship, expanding its European river fleet.
- The vessel will operate on the Rhine, Main, and Danube, supporting capacity growth on core itineraries.
- Committed orderbook targets 18 additional river ships by 2028, lifting the river fleet to 114 ships.
- Plans also call for 11 additional ocean ships by 2032, plus two expedition ships by 2031.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley raises CME Group price target to $337
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.